Replies to post #23740 on Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[leifsmith]

If you had seen what I have seen you would think twice before rejecting positive views as "bias."

Please read this carefully, do a bit of research on the connections of NF-kB and inflammation with a long list of diseases, then ask yourself if people who benefited from anatabine citrate were necessarily just imagining things.

http://investors.rockcreekpharmaceuticals.com/index.php?s=43&item=212

About Anatabine Citrate:
Rock Creek Pharmaceuticals' compound is a small molecule, cholinergic agonist that exhibits anti-inflammatory pharmacological characteristics, distinct from other anti-inflammatory drugs available such as biologics, steroids and non-steroidal anti-inflammatories. The Company has sponsored extensive pre-clinical (in vitro and in vivo) studies resulting in peer reviewed and published scientific journal articles, covering models of Multiple Sclerosis, Alzheimer's Disease, and Auto-Immune Thyroiditis. All these studies demonstrated the anti-inflammatory effects of the Company's compound.

Pay close attention to "cholinergic agonist" - it's important. Notice what drugs anatabine citrate might displace (in part or whole) in the market: "biologics, steroids and non-steroidal anti-inflammatories." This may be important too. It might explain a lot of what has happened.